• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

    5/6/24 6:25:00 AM ET
    $ARYD
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARYD alert in real time by email

    MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

    "When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aspired to involve leading figures in the biotech sector. This Board is fantastic. Our new directors will support Genenta as we aim to consolidate the important results we have achieved so far and to expand the potential impact of our cell therapy for treating tumors," said Pierluigi Paracchi.

    The Company extends its thanks to the former members of its Board for their significant contributions throughout their service.

    John L. Cantello, Ph.D.

    John is an independent advisor to the biopharma industry with over 20 years of experience. John served as the Former VP and Head of Business Development, Oncology Therapy Area at GlaxoSmithKline and VP and Head of BD, Respiratory & Immune Diseases at AstraZeneca. John has led teams accountable for assessing, valuing, and transacting M&A, pipeline & commercial asset deals covering oncology, respiratory, inflammation, metabolic, and rare diseases. He has a track record of closing deals (transacting >$30B in deal value) representing primary care, specialty care, and rare diseases.

    Lauren H. Chung, Ph.D.

    Lauren has over 20 years of operating experience spearheading agile investment management strategies and tactical asset allocation in the healthcare industry. As the founder and CEO of Minleigh LLC, a healthcare focused strategic advisory firm, Lauren has advised leadership, boards, and investment firms on global strategic plans, M&A, integration, and compliance. Previously, Lauren co-founded Tokum Capital Management, a global institutional healthcare fund, and successfully managed its merger with Perella Weinberg Partners. Lauren serves on public and private company boards. She has a Ph.D. in Biomedical Sciences from Columbia University Vagelos College of Physicians and Surgeons, an M.B.A. from Columbia Business School, and a B.A. in Biochemistry and Economics with Honors from Wellesley College.

    Armon R. Sharei, Ph.D.

    Armon is the founder and CEO of Portal Bio and formerly the CEO and founder of SQZ Biotechnologies, where he led the company from invention to post-IPO with over $300 million in equity financing, a $1 billion collaboration with Roche, and three clinical trials. He graduated from Stanford University, and received his Ph.D. at Massachusetts Institute of Technology and his Post-Doctoral at Harvard Medical School.

    Todd Wider, M.D.

    Todd has served as a consultant to numerous entities in the biotechnology space. He is a co-founder and Board member of Xanadu Bio and prior Executive Chairman of Emendo Biotetherapeutics, Board member of Abeona Therapeutics and Arya Science Acquisition Corp IV (NASDAQ:ARYD). Todd is an active, honorary member of the medical staff of Mount Sinai Hospital in New York City. He received his M.D. from Columbia University's Vagelos College of Physicians and Surgeons where he was Rudin Fellow, and an A.B., with high honors and Phi Beta Kappa, from Princeton University. Todd is also a principal in Wider Film Projects, a documentary film company focused on producing films with sociopolitical resonance that have won Academy, Emmy and Peabody Awards.

    Additional information related to the Genenta shareholders' meeting are reported on a Form 6-K filed with the U.S. Securities and Exchange Commission and made available on the Company's website (www.genenta.com).

    About Genenta and Temferon

    Genenta (www.genenta.com) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon, which is under investigation in a phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion and timing of the phase 1/2a clinical trial or any studies relating to the treatment of glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM). Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Genenta's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law.

    Genenta Media: Tiziana Pollio, mobile +39 348 23 15 143 [email protected]



    Primary Logo

    Get the next $ARYD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYD
    $GNTA

    CompanyDatePrice TargetRatingAnalyst
    Genenta Science S.p.A.
    $GNTA
    6/29/2023$15.00Buy
    ROTH MKM
    Genenta Science S.p.A.
    $GNTA
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $ARYD
    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      6/28/24 5:09:55 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      5/10/24 4:31:19 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ARYA Sciences Acquisition Corp IV

      SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      2/14/24 3:30:36 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    $GNTA
    SEC Filings

    See more

    $ARYD
    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 424B5 filed by Genenta Science S.p.A.

      424B5 - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:30:29 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Genenta Science S.p.A.

      20-F - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:25:59 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      3/19/25 9:27:03 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

      ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

      6/29/23 9:11:48 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

      H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

      7/25/22 7:15:53 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

      MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global Biotech Tour" in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million

      4/15/25 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

      MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-pote

      3/19/25 9:28:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    $GNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:52:23 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Henderson Michael Thomas

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:49:31 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Trigg Leslie

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:46:16 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    $GNTA
    Leadership Updates

    Live Leadership Updates

    See more

    $ARYD
    $GNTA
    Financials

    Live finance-specific insights

    See more
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: "Caritas Therapeutics"

      Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A

      9/29/21 6:30:00 AM ET
      $ARYD
      $FOLD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations